ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Helyezés a részvények között
#19253
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Részvényárfolyam
$0.3799409
Piaci kapitalizáció
$159.21M
Változás (1 nap)
-0.34%
Változás (1 év)
-71.81%
Ország
CN
Kereskedés ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategória
Healthcare
Piaci kapitalizációja ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Piaci kapitalizáció: $159.21M
October 2026-ban a ImmuneOnco Biopharmaceuticals (Shanghai) Inc. piaci kapitalizációja $159.21M. Ez alapján a ImmuneOnco Biopharmaceuticals (Shanghai) Inc. a világ 19253rd legértékesebb vállalata a piaci kapitalizáció szerint. A piaci kapitalizáció egy tőzsdén jegyzett vállalat összes részvényének piaci értéke, amelyet gyakran használnak a vállalat értékének mérésére.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. piaci kapitalizációjának története 2023 és 2026 között
1541 összehasonlítva az 5 legnépszerűbb stocks
